Improved biomarkers for prostate cancer: a definite need.
Authors:
- H. Ballentine CarterHCH. Ballentine Carter
- William B. IsaacsWIWilliam B. Isaacs
Open Access
- 1 June 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 96 (11) , 813-5
Abstract
Prostate-specific antigen (PSA) screening for prostate cancer is now widespread in the United States among men of all ages (1). Although prostate cancer mortality has fallen in the United States since the onset of widespread screening, a relationship between screening and the decline in mortality has not been proven.Keywords
This publication has 11 references indexed in Scilit:
- Humoral Immune Response to -Methylacyl-CoA Racemase and Prostate CancerJNCI: Journal of the National Cancer Institute, 2004
- Prostate-Specific Antigen Screening in Elderly MenJNCI: Journal of the National Cancer Institute, 2003
- Genome‐wide scan of Swedish families with hereditary prostate cancer: Suggestive evidence of linkage at 5q11.2 and 19p13.3The Prostate, 2003
- Combining biomarkers to detect disease with application to prostate cancerBiostatistics, 2003
- Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate CancerJNCI: Journal of the National Cancer Institute, 2003
- Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence TrendsJNCI: Journal of the National Cancer Institute, 2002
- α-Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate CancerJAMA, 2002
- P504SAmerican Journal of Surgical Pathology, 2001
- A Genome Screen of Families with Multiple Cases of Prostate Cancer: Evidence of Genetic HeterogeneityThe American Journal of Human Genetics, 2001
- A Prospective Study of Dietary Fat and Risk of Prostate CancerJNCI: Journal of the National Cancer Institute, 1993